Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 109 to 120 of 120 entries
Sorted by: Best Match Show Resources per page
Sex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients.

RMD open

Chimenti MS, Alten R, D'Agostino MA, Gremese E, Kiltz U, Lubrano E, Moreno M, Pham T, Ramonda R, Spinelli FR, Perella C, Andreoli L.
PMID: 34876490
RMD Open. 2021 Dec;7(3). doi: 10.1136/rmdopen-2021-001681.

Emerging evidence suggests that axial spondyloarthritis (axSpA) should not be seen as a predominantly male disease, as the non-radiographic form occurs with roughly equal frequency in women and men. However, men and women experience this disease differently. The purpose...

Cite
Chimenti MS, Alten R, D'Agostino MA, et al. Sex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients. RMD Open. 2021;7(3)doi: 10.1136/rmdopen-2021-001681.
Chimenti, M. S., Alten, R., D'Agostino, M. A., Gremese, E., Kiltz, U., Lubrano, E., Moreno, M., Pham, T., Ramonda, R., Spinelli, F. R., Perella, C., & Andreoli, L. (2021). Sex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients. RMD open, 7(3), . https://doi.org/10.1136/rmdopen-2021-001681
Chimenti, Maria-Sole, et al. "Sex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients." RMD open vol. 7,3 (2021). doi: https://doi.org/10.1136/rmdopen-2021-001681
Chimenti MS, Alten R, D'Agostino MA, Gremese E, Kiltz U, Lubrano E, Moreno M, Pham T, Ramonda R, Spinelli FR, Perella C, Andreoli L. Sex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients. RMD Open. 2021 Dec;7(3). doi: 10.1136/rmdopen-2021-001681. PMID: 34876490; PMCID: PMC8655606.
Copy Download .nbib Format: NLM
Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment.

Rheumatology and therapy

Bessette L, Khraishi M, Kivitz AJ, Kaliyaperumal A, Grantab R, Poulin-Costello M, Isaila M, Collier D.
PMID: 28900875
Rheumatol Ther. 2017 Dec;4(2):391-404. doi: 10.1007/s40744-017-0079-x. Epub 2017 Sep 12.

INTRODUCTION: To evaluate the efficacy and safety of etanercept treatment in adult patients with moderate to severe rheumatoid arthritis (RA) who failed to respond (primary failure) or lost a satisfactory response (secondary failure) to adalimumab.METHODS: All patients discontinued prior...

Cite
Bessette L, Khraishi M, Kivitz AJ, et al. Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment. Rheumatol Ther. 2017;4(2):391-404doi: 10.1007/s40744-017-0079-x.
Bessette, L., Khraishi, M., Kivitz, A. J., Kaliyaperumal, A., Grantab, R., Poulin-Costello, M., Isaila, M., & Collier, D. (2017). Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment. Rheumatology and therapy, 4(2), 391-404. https://doi.org/10.1007/s40744-017-0079-x
Bessette, Louis, et al. "Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment." Rheumatology and therapy vol. 4,2 (2017): 391-404. doi: https://doi.org/10.1007/s40744-017-0079-x
Bessette L, Khraishi M, Kivitz AJ, Kaliyaperumal A, Grantab R, Poulin-Costello M, Isaila M, Collier D. Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment. Rheumatol Ther. 2017 Dec;4(2):391-404. doi: 10.1007/s40744-017-0079-x. Epub 2017 Sep 12. PMID: 28900875; PMCID: PMC5696291.
Copy Download .nbib Format: NLM
Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis.

Rheumatology and therapy

Favalli EG.
PMID: 32734482
Rheumatol Ther. 2020 Sep;7(3):473-516. doi: 10.1007/s40744-020-00219-2. Epub 2020 Jul 30.

Rheumatoid arthritis (RA) is a chronic, debilitating autoimmune disorder involving inflammation and progressive destruction of the joints, affecting up to 1% of the population. The majority of patients with RA have one or more comorbid conditions, the most common...

Cite
Favalli EG. Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis. Rheumatol Ther. 2020;7(3):473-516doi: 10.1007/s40744-020-00219-2.
Favalli, E. G. (2020). Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis. Rheumatology and therapy, 7(3), 473-516. https://doi.org/10.1007/s40744-020-00219-2
Favalli, Ennio G. "Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis." Rheumatology and therapy vol. 7,3 (2020): 473-516. doi: https://doi.org/10.1007/s40744-020-00219-2
Favalli EG. Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis. Rheumatol Ther. 2020 Sep;7(3):473-516. doi: 10.1007/s40744-020-00219-2. Epub 2020 Jul 30. PMID: 32734482; PMCID: PMC7410942.
Copy Download .nbib Format: NLM
Rational use of tocilizumab in COVID-19.

Annals of the rheumatic diseases

Jain S, Sharma SK.
PMID: 32737106
Ann Rheum Dis. 2020 Jul 31; doi: 10.1136/annrheumdis-2020-218519. Epub 2020 Jul 31.

No abstract available.

Cite
Jain S, Sharma SK. Rational use of tocilizumab in COVID-19. Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218519.
Jain, S., & Sharma, S. K. (2020). Rational use of tocilizumab in COVID-19. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218519
Jain, Siddharth, and Sharma, Shefali Khanna. "Rational use of tocilizumab in COVID-19." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218519
Jain S, Sharma SK. Rational use of tocilizumab in COVID-19. Ann Rheum Dis. 2020 Jul 31; doi: 10.1136/annrheumdis-2020-218519. Epub 2020 Jul 31. PMID: 32737106.
Copy Download .nbib Format: NLM
Targeting IL-6 in COVID-19. Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma.

Annals of the rheumatic diseases

Capecchi PL, Lazzerini PE.
PMID: 32737112
Ann Rheum Dis. 2020 Jul 31; doi: 10.1136/annrheumdis-2020-218627. Epub 2020 Jul 31.

No abstract available.

Cite
Capecchi PL, Lazzerini PE. Targeting IL-6 in COVID-19. Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma. Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218627.
Capecchi, P. L., & Lazzerini, P. E. (2020). Targeting IL-6 in COVID-19. Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218627
Capecchi, Pier Leopoldo, and Lazzerini, Pietro Enea. "Targeting IL-6 in COVID-19. Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218627
Capecchi PL, Lazzerini PE. Targeting IL-6 in COVID-19. Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma. Ann Rheum Dis. 2020 Jul 31; doi: 10.1136/annrheumdis-2020-218627. Epub 2020 Jul 31. PMID: 32737112.
Copy Download .nbib Format: NLM
Sex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients.

RMD open

Chimenti MS, Alten R, D'Agostino MA, Gremese E, Kiltz U, Lubrano E, Moreno M, Pham T, Ramonda R, Spinelli FR, Perella C, Andreoli L.
PMID: 34876490
RMD Open. 2021 Dec;7(3). doi: 10.1136/rmdopen-2021-001681.

Emerging evidence suggests that axial spondyloarthritis (axSpA) should not be seen as a predominantly male disease, as the non-radiographic form occurs with roughly equal frequency in women and men. However, men and women experience this disease differently. The purpose...

Cite
Chimenti MS, Alten R, D'Agostino MA, et al. Sex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients. RMD Open. 2021;7(3)doi: 10.1136/rmdopen-2021-001681.
Chimenti, M. S., Alten, R., D'Agostino, M. A., Gremese, E., Kiltz, U., Lubrano, E., Moreno, M., Pham, T., Ramonda, R., Spinelli, F. R., Perella, C., & Andreoli, L. (2021). Sex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients. RMD open, 7(3), . https://doi.org/10.1136/rmdopen-2021-001681
Chimenti, Maria-Sole, et al. "Sex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients." RMD open vol. 7,3 (2021). doi: https://doi.org/10.1136/rmdopen-2021-001681
Chimenti MS, Alten R, D'Agostino MA, Gremese E, Kiltz U, Lubrano E, Moreno M, Pham T, Ramonda R, Spinelli FR, Perella C, Andreoli L. Sex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients. RMD Open. 2021 Dec;7(3). doi: 10.1136/rmdopen-2021-001681. PMID: 34876490; PMCID: PMC8655606.
Copy Download .nbib Format: NLM
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.

Annals of the rheumatic diseases

Machado PM, Lawson-Tovey S, Strangfeld A, Mateus EF, Hyrich KL, Gossec L, Carmona L, Rodrigues A, Raffeiner B, Duarte C, Hachulla E, Veillard E, Strakova E, Burmester GR, Yardımcı GK, Gomez-Puerta JA, Zepa J, Kearsley-Fleet L, Trefond L, Cunha M, Mosca M, Cornalba M, Soubrier M, Roux N, Brocq O, Durez P, Conway R, Goulenok T, Bijlsma JW, McInnes IB, Mariette X.
PMID: 34972811
Ann Rheum Dis. 2021 Dec 31; doi: 10.1136/annrheumdis-2021-221490. Epub 2021 Dec 31.

OBJECTIVES: To describe the safety of vaccines against SARS-CoV-2 in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD).METHODS: Physician-reported registry of I-RMD and non-inflammatory RMD (NI-RMDs) patients vaccinated against SARS-CoV-2. From 5 February 2021 to 27 July 2021, we...

Cite
Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2021-221490.
Machado, P. M., Lawson-Tovey, S., Strangfeld, A., Mateus, E. F., Hyrich, K. L., Gossec, L., Carmona, L., Rodrigues, A., Raffeiner, B., Duarte, C., Hachulla, E., Veillard, E., Strakova, E., Burmester, G. R., Yardımcı, G. K., Gomez-Puerta, J. A., Zepa, J., Kearsley-Fleet, L., Trefond, L., Cunha, M., Mosca, M., Cornalba, M., Soubrier, M., Roux, N., Brocq, O., Durez, P., Conway, R., Goulenok, T., Bijlsma, J. W., McInnes, I. B., & Mariette, X. (2021). Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2021-221490
Machado, Pedro M, et al. "Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2021-221490
Machado PM, Lawson-Tovey S, Strangfeld A, Mateus EF, Hyrich KL, Gossec L, Carmona L, Rodrigues A, Raffeiner B, Duarte C, Hachulla E, Veillard E, Strakova E, Burmester GR, Yardımcı GK, Gomez-Puerta JA, Zepa J, Kearsley-Fleet L, Trefond L, Cunha M, Mosca M, Cornalba M, Soubrier M, Roux N, Brocq O, Durez P, Conway R, Goulenok T, Bijlsma JW, McInnes IB, Mariette X. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2021 Dec 31; doi: 10.1136/annrheumdis-2021-221490. Epub 2021 Dec 31. PMID: 34972811.
Copy Download .nbib Format: NLM
Correspondence on 'Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis'.

Annals of the rheumatic diseases

Reuter K, Rocca E.
PMID: 33593738
Ann Rheum Dis. 2021 Feb 16; doi: 10.1136/annrheumdis-2020-219776. Epub 2021 Feb 16.

No abstract available.

Cite
Reuter K, Rocca E. Correspondence on 'Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis'. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2020-219776.
Reuter, K., & Rocca, E. (2021). Correspondence on 'Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis'. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-219776
Reuter, Katja, and Rocca, Elena. "Correspondence on 'Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis'." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2020-219776
Reuter K, Rocca E. Correspondence on 'Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis'. Ann Rheum Dis. 2021 Feb 16; doi: 10.1136/annrheumdis-2020-219776. Epub 2021 Feb 16. PMID: 33593738.
Copy Download .nbib Format: NLM
Effect of Missed Doses on the Therapeutic Effect of Methotrexate for Rheumatoid Arthritis: A Pharmacokinetic Modeling Study.

Open access rheumatology : research and reviews

Morrison A, Stauffer ME, Kaufman AS.
PMID: 34552357
Open Access Rheumatol. 2021 Sep 14;13:267-274. doi: 10.2147/OARRR.S329178. eCollection 2021.

INTRODUCTION: Patients rarely, if ever, take their medications exactly as prescribed. The extent to which missed doses interfere with a drug's therapeutic effect remains unclear.METHODS: After weekly oral dosing of methotrexate (MTX) for rheumatoid arthritis, its polyglutamate derivatives (MTXglu)...

Cite
Morrison A, Stauffer ME, Kaufman AS. Effect of Missed Doses on the Therapeutic Effect of Methotrexate for Rheumatoid Arthritis: A Pharmacokinetic Modeling Study. Open Access Rheumatol. 2021;13:267-274doi: 10.2147/OARRR.S329178.
Morrison, A., Stauffer, M. E., & Kaufman, A. S. (2021). Effect of Missed Doses on the Therapeutic Effect of Methotrexate for Rheumatoid Arthritis: A Pharmacokinetic Modeling Study. Open access rheumatology : research and reviews, 13267-274. https://doi.org/10.2147/OARRR.S329178
Morrison, Alan, et al. "Effect of Missed Doses on the Therapeutic Effect of Methotrexate for Rheumatoid Arthritis: A Pharmacokinetic Modeling Study." Open access rheumatology : research and reviews vol. 13 (2021): 267-274. doi: https://doi.org/10.2147/OARRR.S329178
Morrison A, Stauffer ME, Kaufman AS. Effect of Missed Doses on the Therapeutic Effect of Methotrexate for Rheumatoid Arthritis: A Pharmacokinetic Modeling Study. Open Access Rheumatol. 2021 Sep 14;13:267-274. doi: 10.2147/OARRR.S329178. eCollection 2021. PMID: 34552357; PMCID: PMC8450605.
Copy Download .nbib Format: NLM
Baseline predictors of different types of treatment success in rheumatoid arthritis.

Annals of the rheumatic diseases

Capelusnik D, Aletaha D.
PMID: 34607792
Ann Rheum Dis. 2021 Oct 04; doi: 10.1136/annrheumdis-2021-220853. Epub 2021 Oct 04.

OBJECTIVE: To perform a comprehensive analysis on predictors of achieving disease activity outcomes by change, response and state measures.METHODS: We used data from three rheumatoid arthritis (RA) trials (one for main analysis, two for validation) to analyse the effect...

Cite
Capelusnik D, Aletaha D. Baseline predictors of different types of treatment success in rheumatoid arthritis. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2021-220853.
Capelusnik, D., & Aletaha, D. (2021). Baseline predictors of different types of treatment success in rheumatoid arthritis. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2021-220853
Capelusnik, Dafne, and Aletaha, Daniel. "Baseline predictors of different types of treatment success in rheumatoid arthritis." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2021-220853
Capelusnik D, Aletaha D. Baseline predictors of different types of treatment success in rheumatoid arthritis. Ann Rheum Dis. 2021 Oct 04; doi: 10.1136/annrheumdis-2021-220853. Epub 2021 Oct 04. PMID: 34607792.
Copy Download .nbib Format: NLM
Anti-cyclic citrullinated peptide antibody (ACPA) and Rheumatoid arthritis: Clinical relevance.

Journal of clinical orthopaedics and trauma

Iyengar KP, Vaish A, Nune A.
PMID: 34926155
J Clin Orthop Trauma. 2021 Dec 01;24:101729. doi: 10.1016/j.jcot.2021.101729. eCollection 2022 Jan.

Rheumatoid Arthritis (RA) is the most common auto-immune, chronic inflammatory joint disease. Predominantly a musculoskeletal condition with a wide spectrum of skeletal and extra-skeletal manifestations, RA has a significant footfall in orthopaedic clinical practice worldwide. RA is essentially a...

Cite
Iyengar KP, Vaish A, Nune A. Anti-cyclic citrullinated peptide antibody (ACPA) and Rheumatoid arthritis: Clinical relevance. J Clin Orthop Trauma. 2021;24:101729doi: 10.1016/j.jcot.2021.101729.
Iyengar, K. P., Vaish, A., & Nune, A. (2022). Anti-cyclic citrullinated peptide antibody (ACPA) and Rheumatoid arthritis: Clinical relevance. Journal of clinical orthopaedics and trauma, 24101729. https://doi.org/10.1016/j.jcot.2021.101729
Iyengar, Karthikeyan P, et al. "Anti-cyclic citrullinated peptide antibody (ACPA) and Rheumatoid arthritis: Clinical relevance." Journal of clinical orthopaedics and trauma vol. 24 (2022): 101729. doi: https://doi.org/10.1016/j.jcot.2021.101729
Iyengar KP, Vaish A, Nune A. Anti-cyclic citrullinated peptide antibody (ACPA) and Rheumatoid arthritis: Clinical relevance. J Clin Orthop Trauma. 2021 Dec 01;24:101729. doi: 10.1016/j.jcot.2021.101729. eCollection 2022 Jan. PMID: 34926155; PMCID: PMC8649790.
Copy Download .nbib Format: NLM
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases.

Annals of the rheumatic diseases

Boyarsky BJ, Ruddy JA, Connolly CM, Ou MT, Werbel WA, Garonzik-Wang JM, Segev DL, Paik JJ.
PMID: 33757968
Ann Rheum Dis. 2021 Mar 23; doi: 10.1136/annrheumdis-2021-220289. Epub 2021 Mar 23.

No abstract available.

Cite
Boyarsky BJ, Ruddy JA, Connolly CM, et al. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2021-220289.
Boyarsky, B. J., Ruddy, J. A., Connolly, C. M., Ou, M. T., Werbel, W. A., Garonzik-Wang, J. M., Segev, D. L., & Paik, J. J. (2021). Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2021-220289
Boyarsky, Brian J, et al. "Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2021-220289
Boyarsky BJ, Ruddy JA, Connolly CM, Ou MT, Werbel WA, Garonzik-Wang JM, Segev DL, Paik JJ. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021 Mar 23; doi: 10.1136/annrheumdis-2021-220289. Epub 2021 Mar 23. PMID: 33757968.
Copy Download .nbib Format: NLM
Showing 109 to 120 of 120 entries